Wall Street analysts forecast that Tabula Rasa HealthCare Inc (NASDAQ:TRHC) will report $0.19 earnings per share (EPS) for the current quarter, according to Zacks. Six analysts have made estimates for Tabula Rasa HealthCare’s earnings, with the highest EPS estimate coming in at $0.32 and the lowest estimate coming in at $0.00. Tabula Rasa HealthCare reported earnings per share of $0.09 in the same quarter last year, which would suggest a positive year over year growth rate of 111.1%. The firm is expected to report its next quarterly earnings results on Monday, March 11th.

According to Zacks, analysts expect that Tabula Rasa HealthCare will report full-year earnings of $0.77 per share for the current year, with EPS estimates ranging from $0.56 to $0.96. For the next financial year, analysts expect that the business will post earnings of $1.07 per share, with EPS estimates ranging from $0.79 to $1.50. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that cover Tabula Rasa HealthCare.

Tabula Rasa HealthCare (NASDAQ:TRHC) last issued its quarterly earnings results on Tuesday, November 6th. The company reported $0.26 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.19 by $0.07. The company had revenue of $54.42 million for the quarter, compared to analysts’ expectations of $52.87 million. Tabula Rasa HealthCare had a positive return on equity of 7.63% and a negative net margin of 13.49%. The firm’s revenue for the quarter was up 66.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.08 earnings per share.

TRHC has been the topic of a number of recent research reports. Citigroup increased their target price on Tabula Rasa HealthCare from $57.00 to $76.00 and gave the stock a “buy” rating in a research note on Thursday, August 9th. Piper Jaffray Companies increased their target price on Tabula Rasa HealthCare to $71.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 8th. Stifel Nicolaus initiated coverage on Tabula Rasa HealthCare in a research note on Tuesday, September 11th. They issued a “hold” rating and a $95.00 target price on the stock. Cantor Fitzgerald initiated coverage on Tabula Rasa HealthCare in a research note on Thursday, September 6th. They issued an “overweight” rating and a $99.00 target price on the stock. Finally, Zacks Investment Research cut Tabula Rasa HealthCare from a “buy” rating to a “hold” rating in a research note on Tuesday, August 14th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $81.60.

TRHC stock traded down $1.97 during midday trading on Wednesday, hitting $62.79. The stock had a trading volume of 278,679 shares, compared to its average volume of 346,076. The stock has a market cap of $1.33 billion, a price-to-earnings ratio of -1,569.75, a PEG ratio of 6.16 and a beta of 2.58. Tabula Rasa HealthCare has a 52-week low of $27.25 and a 52-week high of $91.16. The company has a quick ratio of 0.46, a current ratio of 0.49 and a debt-to-equity ratio of 0.28.

In related news, CEO Calvin H. Knowlton sold 8,000 shares of the stock in a transaction on Friday, September 7th. The stock was sold at an average price of $85.98, for a total transaction of $687,840.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders have sold 48,000 shares of company stock worth $3,722,960 over the last ninety days. 14.00% of the stock is currently owned by insiders.

Institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its holdings in Tabula Rasa HealthCare by 20.8% in the third quarter. BlackRock Inc. now owns 2,560,710 shares of the company’s stock valued at $207,904,000 after acquiring an additional 441,203 shares during the period. Jennison Associates LLC grew its holdings in Tabula Rasa HealthCare by 29.5% during the 2nd quarter. Jennison Associates LLC now owns 757,846 shares of the company’s stock valued at $48,373,000 after buying an additional 172,693 shares in the last quarter. NN Investment Partners Holdings N.V. grew its holdings in Tabula Rasa HealthCare by 45.2% during the 3rd quarter. NN Investment Partners Holdings N.V. now owns 669,800 shares of the company’s stock valued at $54,380,000 after buying an additional 208,604 shares in the last quarter. Braun Stacey Associates Inc. grew its holdings in Tabula Rasa HealthCare by 199.0% during the 2nd quarter. Braun Stacey Associates Inc. now owns 301,089 shares of the company’s stock valued at $19,219,000 after buying an additional 200,394 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in Tabula Rasa HealthCare by 20.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 258,613 shares of the company’s stock valued at $20,996,000 after buying an additional 44,551 shares in the last quarter. 75.36% of the stock is currently owned by institutional investors.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. It offers medication risk management, pharmacy cost management, and medicare risk adjustment services. The company offers its technology-enabled products and services to prescribers, pharmacists, and healthcare organizations for medication risk management and risk adjustment.

Recommended Story: Investing strategies using the yield curve

Get a free copy of the Zacks research report on Tabula Rasa HealthCare (TRHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.